A landmark study of 215,695 people proves it. Your cholesterol panel alone can't see it. But a single genome test — read once — predicts your lifetime heart attack risk more accurately than any traditional methodology.

They had checkups. They knew their cholesterol. Some even had “good” numbers. What they didn't know — what no standard test measured — was the genetic blueprint already shaping their risk since birth.
The science is clear. The tools now exist. The question is whether you choose to look.
"She had a normal physical every year. Normal cholesterol. The heart attack came at 47."
Her genome would have flagged it at 35.
Blood pressure, cholesterol, and an EKG measure the consequences of years of biological processes already underway. They're essential — but they're looking at the past. Your genome is the blueprint. It tells you what's coming.
Built on research published in the Journal of the American College of Cardiology, Human Longevity's 4-biomarker algorithm — combining your genetic risk score with lipid and inflammation markers — dramatically outperforms standard care at identifying who needs intervention now.
Farah W. et al., "The Biological Blueprint of Coronary Risk." Journal of the American College of Cardiology (JACC), 2026. UK Biobank, N=215,695, 12-year follow-up. Hazard ratios adjusted for age, sex, and traditional risk factors.
In the JACC study, the 4-biomarker algorithm was most powerful in patients aged 40–49 — because biological risk accumulates decades before any symptom appears. The genome was always there, but the window to act early is closing.
One saliva sample. Sequenced once in a CLIA-certified lab at 30× clinical coverage. Returns a physician-ready report your cardiologist can act on.
Your individual lifetime genetic risk for heart attack — calibrated against data from hundreds of thousands of sequenced genomes. The single most powerful predictor of cardiac risk available today. Standard care never measures it.
Variants in PCSK9, LDLR, and APOB — the three genes that cause inherited high cholesterol regardless of diet or exercise. 1 in 250 people carry one. 90% have never been told.
Lipoprotein(a) drives 1 in 5 heart attacks and is almost entirely written in your DNA. It does not respond to statins. Most cardiologists have never tested for it. Knowing unlocks emerging RNA-interference therapies.
Long QT syndrome, hypertrophic cardiomyopathy, Brugada syndrome — inherited conditions that cause sudden cardiac death in people with no prior symptoms.
Your genes determine how you metabolize statins, anticoagulants, and beta-blockers. Knowing this helps your physician prescribe the right drug, at the right dose, on the first try.
Your genome doesn't change. The science does. Every year, we re-run your data through the latest published algorithms and update your report with any new clinically actionable findings. At no additional cost. Ever.
No clinic visit required. Kit ships to your door in 2 business days. HSA and FSA eligible.
Kit ships in 2 business days. $599, one-time. HSA/FSA accepted. No clinic visit required.
A simple saliva collection. Takes 5 minutes at home. Mail it back in the prepaid envelope.
Processed in a CLIA-certified lab. 30× whole genome coverage. AI-analyzed against the largest private genomic database in the world.
Clinician-formatted PDF in 4–6 weeks. Physician-ready. Share directly with your cardiologist or primary care physician.
Questions from real patients who've taken the test or are considering it.
Around 1 million Americans will have a heart attack this year. Half are carrying genetic risk their doctors have never seen. For $599 — one-time, HSA/FSA eligible — you can see yours.
Primary Citation: Farah, R. et al. Combining genomics with lipid and inflammatory biomarkers to predict coronary artery disease risk: UK Biobank study. J. Am. Coll. Cardiol. 87, 2785–2803 (2026). UK Biobank, N=215,695, 12-year follow-up. · This page is for educational purposes. Individual results vary. Heart attack risk prediction and prevention requires evaluation by a licensed clinician. Human Longevity, Inc. is not the author of the referenced study.